Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 4:05 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1129–1152 of 4,209 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Injectable Placebo Clear all
Withdrawn Early Phase 1 Interventional Accepts healthy volunteers

J-Tip® Jet Injection of 1% Buffered Lidocaine or Saline Versus 4% Lidocaine Cream Before Venipuncture or IV Insertion

NCT00924963
View directory record Official record
Conditions
Pain
Interventions
J-Tip jet injector, Jet injection saline, lidocaine cream
Device · Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
7 Years to 21 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
Liberty Township, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 21, 2020 · Synced Oct 22, 2026, 4:05 AM EDT
Terminated Phase 3 Interventional

Evaluation of Weekly Idrabiotaparinux Sodium Versus Oral Adjusted-dose Warfarin to Prevent Stroke and Systemic Thromboembolic Events in Patients With Atrial Fibrillation

NCT00580216
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
Idrabiotaparinux sodium, Warfarin, Placebo (for idrabiotaparinux), Placebo (for warfarin), Avidin, Placebo (for avidin)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
3,773 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
162
States / cities
Mobile, Alabama • Tucson, Arizona • Little Rock, Arkansas + 134 more
Source: ClinicalTrials.gov public record
Updated Mar 21, 2016 · Synced Oct 22, 2026, 4:05 AM EDT
Active, not recruiting Phase 1 Interventional

Study of ALV-100 to Assess Safety, Tolerability, and PK/PD in Overweight/Obese Participants With or Without T2D

NCT07399678
View directory record Official record
Conditions
Overweight or Obese Adults, Overweight or Obese, Type 2 Diabetes
Interventions
ALV-100, Placebo
Drug
Lead sponsor
Alveus Therapeutics, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
3
States / cities
Miami, Florida • Columbus, Ohio • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 22, 2026, 4:05 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Placebo-controlled Safety and Tolerability Study of Intravenous (IV) and Subcutaneous (SC) AZD1163 in Healthy Volunteers

NCT06103877
View directory record Official record
Conditions
Healthy Volunteers
Interventions
AZD1163, Placebo
Biological · Other
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years
Enrollment
108 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
2
States / cities
Glendale, California • Brooklyn, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 27, 2026 · Synced Oct 22, 2026, 4:05 AM EDT
Terminated Phase 2 Interventional Results available

Allogeneic Myeloma GM-CSF Vaccine With Lenalidomide in Multiple Myeloma Patients in Complete or Near Complete Remission

NCT03376477
View directory record Official record
Conditions
Multiple Myeloma
Interventions
GM-CSF vaccine, Lenalidomide, Prevnar13, Placebo Prevnar13, Placebo GM-CSF Vaccine
Biological · Drug · Other
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 27, 2025 · Synced Oct 22, 2026, 4:05 AM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers

Impact of a Booster Course of Antenatal Steroids on Neonatal Outcome in Patients With Premature Rupture of the Membranes

NCT02469519
View directory record Official record
Conditions
Premature Birth
Interventions
Betamethasone - ACTIVE, Normal Saline - PLACEBO
Drug · Other
Lead sponsor
Pediatrix
Other
Eligibility
18 Years to 65 Years · Female only
Enrollment
194 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2022
U.S. locations
9
States / cities
Mobile, Alabama • Phoenix, Arizona • Long Beach, California + 6 more
Source: ClinicalTrials.gov public record
Updated Dec 15, 2022 · Synced Oct 22, 2026, 4:05 AM EDT
Completed Phase 3 Interventional Results available

Evaluation of Dupilumab in Patients With Severe Steroid Dependent Asthma

NCT02528214
View directory record Official record
Conditions
Asthma
Interventions
Dupilumab, Placebo, Oral corticosteroid therapy (prednisone/prednisolone), Inhaled corticosteroid (ICS) therapy, Albuterol/Salbutamol, Levalbuterol/Levosalbutamol
Drug
Lead sponsor
Sanofi
Industry
Eligibility
12 Years and older
Enrollment
210 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
8
States / cities
Los Angeles, California • Rolling Hills Estates, California • St Louis, Missouri + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2019 · Synced Oct 22, 2026, 4:05 AM EDT
Active, not recruiting Phase 3 Interventional Results available

A Phase III Study to Evaluate the Efficacy and Safety of Benralizumab in Patients With Hypereosinophilic Syndrome (HES)

NCT04191304
View directory record Official record
Conditions
Hypereosinophilic Syndrome
Interventions
Benralizumab, Placebo
Biological
Lead sponsor
AstraZeneca
Industry
Eligibility
12 Years to 130 Years
Enrollment
134 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
8
States / cities
La Jolla, California • Atlanta, Georgia • Bethesda, Maryland + 5 more
Source: ClinicalTrials.gov public record
Updated Jul 10, 2026 · Synced Oct 22, 2026, 4:05 AM EDT
Completed Phase 2 Interventional Results available

Study of the Intradermal Injection of rHuPH20 or Placebo in Participants With Nickel Allergic Contact Dermatitis

NCT00928447
View directory record Official record
Conditions
Dermatitis, Allergic Contact
Interventions
rHuPH20, Placebo
Drug
Lead sponsor
Halozyme Therapeutics
Industry
Eligibility
18 Years to 60 Years · Female only
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
1
States / cities
Michigan City, Indiana
Source: ClinicalTrials.gov public record
Updated Dec 17, 2021 · Synced Oct 22, 2026, 4:05 AM EDT
Completed Phase 4 Interventional Results available

Controlled Study of Humira in Subjects With Chronic Plaque Psoriasis of the Hands and/or Feet

NCT00735787
View directory record Official record
Conditions
Psoriasis
Interventions
Placebo, Adalimumab
Biological
Lead sponsor
Abbott
Industry
Eligibility
18 Years and older
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
8
States / cities
Little Rock, Arkansas • Bakersfield, California • Macon, Georgia + 5 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2010 · Synced Oct 22, 2026, 4:05 AM EDT
Completed Phase 2 Interventional Results available

Clonidine Versus Adenosine to Treat Neuropathic Pain

NCT00349921
View directory record Official record
Conditions
Pain
Interventions
clonidine, adenosine, placebo
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
Not listed
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
2
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 10, 2018 · Synced Oct 22, 2026, 4:05 AM EDT
Completed Phase 1 Interventional

Single Ascending Dose of AMG 609 in Participants With Non-alcoholic Fatty Liver Disease

NCT04857606
View directory record Official record
Conditions
Non-alcoholic Fatty Liver Disease
Interventions
AMG 609, Placebo
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 70 Years
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
10
States / cities
Chandler, Arizona • Chula Vista, California • Montclair, California + 5 more
Source: ClinicalTrials.gov public record
Updated Nov 7, 2023 · Synced Oct 22, 2026, 4:05 AM EDT
Completed Phase 3 Interventional Results available

Research Study Investigating How Well Semaglutide Works in People Suffering From Overweight or Obesity

NCT03548987
View directory record Official record
Conditions
Metabolism and Nutrition Disorder, Obesity
Interventions
Semaglutide, Placebo
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
902 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
28
States / cities
Anniston, Alabama • Fresno, California • San Diego, California + 22 more
Source: ClinicalTrials.gov public record
Updated Jan 19, 2022 · Synced Oct 22, 2026, 4:05 AM EDT
Completed Phase 2 Interventional

Dose Finding Study of Bone Morphogenetic Protein 7 (BMP-7) in Subjects With Osteoarthritis (OA) of the Knee

NCT01111045
View directory record Official record
Conditions
Osteoarthritis of the Knee
Interventions
Bone morphogenetic protein 7, Placebo
Drug
Lead sponsor
Stryker Biotech
Industry
Eligibility
40 Years and older
Enrollment
355 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
25
States / cities
Glendale, Arizona • Tucson, Arizona • Palo Alto, California + 20 more
Source: ClinicalTrials.gov public record
Updated Feb 1, 2012 · Synced Oct 22, 2026, 4:05 AM EDT
Completed Phase 1 Interventional

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Response of Vasomera (PB1046) Injection Following a Single Subcutaneous Dose in Subjects With Stage 1 or 2 Essential Hypertension

NCT01523067
View directory record Official record
Conditions
Essential Hypertension
Interventions
Vasomera (PB1046), 0.9% Sodium Chloride
Drug
Lead sponsor
PhaseBio Pharmaceuticals Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
5
States / cities
Anniston, Alabama • Walnut Creek, California • Saint Paul, Minnesota + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 4, 2013 · Synced Oct 22, 2026, 4:05 AM EDT
Terminated Phase 2 Interventional

Phase 2B Micronized DHACM vs. Saline in the Treatment of Knee Osteoarthritis

NCT05796765
View directory record Official record
Conditions
Knee Osteoarthritis
Interventions
Micronized DHACM 40 mg, Micronized DHACM 100 mg, Saline
Biological · Drug
Lead sponsor
MiMedx Group, Inc.
Industry
Eligibility
21 Years to 80 Years
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
14
States / cities
La Mesa, California • Miami, Florida • The Villages, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Jan 17, 2024 · Synced Oct 22, 2026, 4:05 AM EDT
Completed Phase 3 Interventional Results available

A Phase 3 Study in Participants With Moderate to Severe Psoriasis (UNCOVER-2)

NCT01597245
View directory record Official record
Conditions
Psoriasis
Interventions
80 mg ixekizumab Dosing Regimen, 50 mg etanercept, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
1,224 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
41
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Little Rock, Arkansas + 38 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2020 · Synced Oct 22, 2026, 4:05 AM EDT
Completed Phase 2Phase 3 Interventional Results available

An Efficacy and Safety Study of Golimumab (CNTO 148) in Participants With Moderately to Severely Active Ulcerative Colitis

NCT00487539
View directory record Official record
Conditions
Colitis, Ulcerative
Interventions
Placebo, Golimumab 100 mg, Golimumab 200 mg, Golimumab 400 mg, Golimumab 50 mg
Biological
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
1,065 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
58
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Roseville, California + 55 more
Source: ClinicalTrials.gov public record
Updated Feb 17, 2014 · Synced Oct 22, 2026, 4:05 AM EDT
Completed Phase 3 Interventional Results available

Lume Lung 2 : BIBF 1120 Plus Pemetrexed Compared to Placebo Plus Pemetrexed in 2nd Line Nonsquamous NSCLC

NCT00806819
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
Nintedanib (BIBF1120), Pemetrexed, B12, dexamethasone (or corticosteroid equivalent), placebo, Folic Acid
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
718 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
40
States / cities
Downy, California • Fountain Valley, California • Fullerton, California + 37 more
Source: ClinicalTrials.gov public record
Updated Feb 2, 2017 · Synced Oct 22, 2026, 4:05 AM EDT
Recruiting Phase 4 Interventional

Inclisiran Versus Placebo for the Prevention of Major Adverse Cardiovascular and Limb Events in Patients Undergoing Percutaneous Coronary Intervention or Peripheral Endovascular Intervention

NCT06909565
View directory record Official record
Conditions
Percutaneous Coronary Intervention, Peripheral Endovascular Intervention
Interventions
Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL, Normal Saline (Placebo)
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
6,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
145
States / cities
Alexander City, Alabama • Birmingham, Alabama • Huntsville, Alabama + 129 more
Source: ClinicalTrials.gov public record
Updated Oct 19, 2026 · Synced Oct 22, 2026, 4:05 AM EDT
Active, not recruiting Phase 3 Interventional

A Clinical Trial to Evaluate Efficacy and Safety of Xeomin® Injections for Preventing Episodic Migraine

NCT07018700
View directory record Official record
Conditions
Episodic Migraine
Interventions
Xeomin, Placebo
Drug
Lead sponsor
Merz Therapeutics GmbH
Industry
Eligibility
18 Years and older
Enrollment
997 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
47
States / cities
Chandler, Arizona • Phoenix, Arizona • Little Rock, Arkansas + 43 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2026 · Synced Oct 22, 2026, 4:05 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetics, Safety, and Tolerability of Intramuscular 5-MeO-DMT in Healthy Volunteers

NCT05698095
View directory record Official record
Conditions
Pharmacokinetics, Safety, Tolerability
Interventions
5-methoxy-N,N-dimethyltryptamine succinate salt, Placebo
Drug
Lead sponsor
Usona Institute
Other
Eligibility
18 Years to 65 Years
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Nov 30, 2023 · Synced Oct 22, 2026, 4:05 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluation of the Safety, Pharmacokinetics, and Preliminary Effect on Scar Formation by RXI-109

NCT01640912
View directory record Official record
Conditions
Cicatrix, Scar Prevention
Interventions
RXI-109, Placebo
Drug
Lead sponsor
RXi Pharmaceuticals, Corp.
Industry
Eligibility
21 Years to 50 Years · Female only
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Sep 17, 2014 · Synced Oct 22, 2026, 4:05 AM EDT
Completed Phase 3 Interventional Results available

Study of an Investigational Drug for the Prevention of Thrombosis-related Events Following Hip Replacement Surgery (ADVANCE-3)

NCT00423319
View directory record Official record
Conditions
Deep Vein Thrombosis, Pulmonary Embolism
Interventions
Enoxaparin, Apixaban, Enoxaparin-matching placebo, Apixaban-matching placebo
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
5,407 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
19
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Sacramento, California + 12 more
Source: ClinicalTrials.gov public record
Updated May 14, 2014 · Synced Oct 22, 2026, 4:05 AM EDT